Literature DB >> 8794347

Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.

H Zhou1, W O'Neal, N Morral, A L Beaudet.   

Abstract

Although adenovirus vectors offer many advantages, it would be desirable to develop vectors with improved expression and decreased toxicity. Toward this objective, an adenovirus vector system with deletion of both the El and E2a regions was developed. A 5.9-kb fragment of the adenovirus type 5 (Ad5) genome containing the E2a gene and its early and late promoters was transfected into 293 cells. A complementing cell line, designated 293-C2, expressed the E2a mRNA and protein and was found to complement the defect in Ad5 viruses with temperature-sensitive or deletion mutations in E2a. A deletion of 1.3 kb removing codons 40 to 471 of the 529 amino acids of E2a was introduced into plasmids for preparation of viruses and vectors. An Ad5 virus with disruption of the El gene and deletion of E2a grew on 293-C2 cells but not on 293 cells. Vectors with E1 and E2a deleted expressing Escherichia coli beta-galactosidase or human alpha1-antitrypsin were prepared and expressed the reporter genes after intravenous injection into mice. This vector system retains sequences in common between the complementing cell line and the vectors, including 3.4 kb upstream and 1.1 kb downstream of the deletion. These vectors have potential advantages of increased capacity for insertion of transgene sequences, elimination of expression of E2a, and possibly reduction in expression of other viral proteins. Although the titers of the vectors with deleted are about 10- to 30-fold below those of vectors with E2a wild-type regions, the former vectors are suitable for detailed studies with animals to evaluate the effects on host immune responses, on duration of expression, and on safety.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794347      PMCID: PMC190753     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  IMMUNIZATION WITH TYPES 4 AND 7 ADENOVIRUS BY SELECTIVE INFECTION OF THE INTESTINAL TRACT.

Authors:  R B COUCH; R M CHANOCK; T R CATE; D J LANG; V KNIGHT; R J HUEBNER
Journal:  Am Rev Respir Dis       Date:  1963-09

2.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

3.  Mutually exclusive interaction of the adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1.

Authors:  R J O'Connor; P Hearing
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

Authors:  J F Engelhardt; X Ye; B Doranz; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

5.  Construction, characterization, and utilization of cell lines which inducibly express the adenovirus DNA-binding protein.

Authors:  D E Brough; V Cleghon; D F Klessig
Journal:  Virology       Date:  1992-10       Impact factor: 3.616

6.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.

Authors:  A J Bett; W Haddara; L Prevec; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

7.  Evaluation of the efficacy and safety of in vitro, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA.

Authors:  N Mittereder; S Yei; C Bachurski; J Cuppoletti; J A Whitsett; P Tolstoshev; B C Trapnell
Journal:  Hum Gene Ther       Date:  1994-06       Impact factor: 5.695

8.  Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes.

Authors:  M A Morsy; E L Alford; A Bett; F L Graham; C T Caskey
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

Review 9.  Cell and gene therapy in Duchenne muscular dystrophy.

Authors:  J E Morgan
Journal:  Hum Gene Ther       Date:  1994-02       Impact factor: 5.695

10.  Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis.

Authors:  Y Yang; F A Nunes; K Berencsi; E Gönczöl; J F Engelhardt; J M Wilson
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

View more
  17 in total

1.  Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication.

Authors:  J E Nelson; M A Kay
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Effect of the E4 region on the persistence of transgene expression from adenovirus vectors.

Authors:  D Armentano; J Zabner; C Sacks; C C Sookdeo; M P Smith; J A St George; S C Wadsworth; A E Smith; R J Gregory
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted.

Authors:  A Amalfitano; M A Hauser; H Hu; D Serra; C R Begy; J S Chamberlain
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

4.  Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo.

Authors:  S C Wadsworth; H Zhou; A E Smith; J M Kaplan
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia.

Authors:  B Lee; J A Dennis; P J Healy; B Mull; L Pastore; H Yu; E Aguilar-Cordova; W O'Brien; P Reeds; A L Beaudet
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.

Authors:  N Morral; W O'Neal; K Rice; M Leland; J Kaplan; P A Piedra; H Zhou; R J Parks; R Velji; E Aguilar-Córdova; S Wadsworth; F L Graham; S Kochanek; K D Carey; A L Beaudet
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

7.  A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette.

Authors:  Hongjie Wang; André Lieber
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

8.  In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.

Authors:  M Lusky; M Christ; K Rittner; A Dieterle; D Dreyer; B Mourot; H Schultz; F Stoeckel; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.

Authors:  A Lieber; C Y He; I Kirillova; M A Kay
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

10.  Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication.

Authors:  Xinyu Zheng; Xiao-Mei Rao; Jorge G Gomez-Gutierrez; Hongying Hao; Kelly M McMasters; H Sam Zhou
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.